Maker of Botox Rival Soars as Treatment May Win Approval By February
This article is for subscribers only.
The first new aesthetic neurotoxin to rival Allergan Plc’s Botox in almost a decade may be approved in time for Valentine’s Day.
Evolus Inc. Chief Executive Officer David Moatazedi says his company remains on track for a spring 2019 launch for its experimental wrinkle treatment, DWP-450. The Food and Drug Administration is now expected to make a decision on the drug by February 2 after the company failed to secure approval in May when the agency had questions on the company’s chemistry, manufacturing and controls processes.